A complete sample of the Manufacturer Shortlist deliverable, built to a representative
client profile — a Netherlands hospital-channel distributor — to show the exact standard
of a delivered engagement. The suppliers, certifications, pricing, and freight rates inside
are real, current, and independently verified. Only the client profile is representative.
Kangyou is the primary recommendation for standard disposables: CE MDR valid to March 2030 — the longest of the three presented — and the lowest landed cost.
Finding 02 — Specialisation
Yesomed (subsidiary of Shenzhen-listed Suzhou Tianhua, 300390) is the only presented supplier making safety and auto-disable syringes with CE MDR and ISO 13485 standing, backed by WHO PQS (E008) for auto-disable. For EU safety-syringe lines it is the only qualified option in this evaluation.
Finding 03 — Exclusions
Two of six evaluated suppliers were excluded — one on MOQ and port constraints, one on unresolved CE MDR transition status. Under current EU MDR enforcement, a pending certificate is a supply risk, not a discount opportunity. Both exclusions are documented on the Not Recommended pages.
Primary Risk
No unresolved regulatory questions remain among the three presented suppliers — every certification was verified current against issuing-body records. The remaining gap is physical: no on-site GMP audit has been conducted. Commission one before large-volume commitment.
Recommended strategy for this profile
Primary
Kangyou — standard disposables, MDR 2030, lowest landed cost
Safety lines
Yesomed — safety & auto-disable syringes, WHO PQS, CE MDR
Needles / Backup / Entry
Qiaosend — needle sourcing, backup supply, low-MOQ entry at 100,000 units
Representative — EU wholesale channel, benchmarked at market rates
Key Requirements
CE MDR-compliant manufacturers · ISO 13485 audited by recognised body · EO sterilisation with ISO 11135 validation documentation available · Minimum 2 qualified backup suppliers · FOB pricing with CIF Rotterdam calculation including EU ETS
HIELUX
04
Verification Methodology
What was verified. What was not.
Every claim in this report is sourced. Where verification was not possible or not performed, that is stated explicitly.
Hielux Advisory holds no commercial relationship with any manufacturer in this report. No referral fee, commission, or compensation of any kind was received or solicited. Every assessment reflects independent evaluation against the stated profile only.
Verified
Direct supplier engagement
Each shortlisted supplier maintains a named account contact assigned to Hielux's category inquiries. Pricing, MOQ, lead times, payment terms, and certification documentation were obtained directly through these contacts via written correspondence and video calls during the evaluation period. No supplier was informed of this report or its intended recipient in advance.
Certification cross-reference
CE MDR, FDA (K053519), ISO 13485, and WHO PQS (E008) verified against issuing body records and WHO PQS public database. All further national registrations were confirmed via manufacturer documentation and public registries.
Parent company verification
Yesomed confirmed as wholly-owned subsidiary of Suzhou Tianhua Super Clean Technology Co., Ltd. (Shenzhen Stock Exchange: 300390). Registered capital RMB 60 million confirmed via public filings.
Freight and landed cost
Ocean freight rates were sourced from the Drewry World Container Index (week of July 16, 2026). EU ETS surcharges were cross-referenced against carrier market rates published by Searoutes and CMA CGM (2026, full ETS phase-in basis).
Documentation obtained & included
Original certificates, current scope documents, declarations, and current compliance status were obtained directly from each manufacturer, verified against issuing-body and public records, and are included with this report. Hielux re-verifies on renewal or scope change.
Recommended before large-volume commitment
Physical factory audit
No on-site inspection was conducted. Physical GMP audit should be commissioned independently before large-volume commitment. Recommended for orders above USD 50,000.
EO sterilisation validation records
EO sterilisation was confirmed as the method used. The ISO 11135 validation file — sterilisation cycle validation, bioburden data, sterility assurance level records — is collected from the manufacturer during sample qualification, which Hielux coordinates.
Production batch quality
Sample quality evaluated for Yesomed only. Pre-production sample evaluation recommended for all other suppliers before first commercial order.
HIELUX
05
Evaluation Process
How we arrived at these three.
Six manufacturers were shortlisted from a broader Asia-wide pool and evaluated in detail against this profile. Three met the criteria in full; two did not; one fell outside scope.
1
2
3
×
×
—
3 presentedKangyou · Yesomed · Qiaosend — certifications verified current
2 not recommendedINI — MDR pending · Haiou — MOQ & port
1 outside scope
Procurement Scorecard
Supplier
MDR Standing
Reg. Risk
FOB Price
MOQ Flex.
Cert. Depth
Product Breadth
Best Use
Yesomed
A
Low
C
B
A
A
Safety / auto-disable / WHO PQS
Kangyou
A
Low
A
B
B
B
Standard primary supplier
Qiaosend
A
Low
B
A
B
B
Needles / backup source
How to read the grades: MDR standing scores the documented EU position — certificate standing and compliance chain. All three presented suppliers hold CE MDR verified current — Kangyou dated to March 2030, Qiaosend to July 2029, Yesomed's certificate on file — with complete EU chains: A across the board. Suppliers that could not clear this bar were removed before presentation. Differentiation between the three sits in price, MOQ, certification depth, and product breadth. Reg. Risk asks whether the certification is certain for EU hospital supply — all three pass at Low; the evaluated supplier that did not is on the Not Recommended pages. A = Strong, B = Adequate, C = Weaker relative to this profile.
Commercial terms at a glance
Supplier
FOB port
Standard MOQ
Lead time
Payment
Kangyou
Shanghai
200,000 units
30 days from deposit
30% deposit · 70% before shipment
Yesomed
Shanghai
200,000 units
30 days from deposit
30% deposit · 70% before shipment
Qiaosend
Qingdao
100,000 units
30 days from deposit
30% deposit · 70% before shipment
Terms confirmed directly with each supplier during evaluation. Volume terms open with a documented commitment of quantity and timeline — not at first-inquiry stage.
HIELUX
06
Supply Chain Overview
Where this quote sits in the cycle — and three supplier lanes.
All three suppliers ship Rotterdam on the Asia–North Europe lane. Freight is quoted at the Drewry WCI reading of July 16, 2026 — taken at peak season, which makes the savings in this report conservative.
Freight tripled in ten weeks — this report prices at the peak
Spot rate, Shanghai → Rotterdam, USD per 40ft container
Source: Drewry World Container Index. Weekly readings Jun 25 – Jul 16, 2026 plotted exactly; earlier curve indicative between published anchors.
Supplier lanes · Cape of Good Hope routing
Supplier
Origin port
Transit
Destination
Kangyou
Shanghai
35–45 days
Rotterdam · ECT Maasvlakte
Yesomed
Shanghai
35–45 days
Rotterdam · ECT Maasvlakte
Qiaosend
Qingdao
38–48 days
Rotterdam · ECT Maasvlakte
Freight reference — Shanghai / Qingdao to Rotterdam · July 2026
40HQ Ocean
$4,873
EU ETS surcharge
$168 / 40HQ
LCL ocean
$70 / CBM
Source
Drewry WCI
Qingdao to Rotterdam is approximately $50–80 per 40HQ above Shanghai rates on the same lane due to port positioning. As of July 2026, Cape of Good Hope remains the standard routing for Asia–North Europe: Red Sea / Suez transit is still suspended for most services after Houthi attacks resumed in early 2026, with carriers returning to the Suez lane only selectively — CMA CGM has signalled a fuller return and Maersk has run trial transits as conditions allow. Cape routing adds roughly 10–14 days versus the pre-disruption Suez transit. Spot rates sit at peak-season levels — Shanghai–Rotterdam rose through early July before easing 1% in the week of July 16, with mid-July general rate increases in force — and remain volatile; confirm routing, transit time, and surcharges with your freight forwarder at booking.
HIELUX
07
Price Comparison
All three factories, side by side.
Factory-direct FOB pricing for the standard disposable and insulin lines — the products all three factories make. The lowest price in each row is highlighted. Specialty lines (auto-disable, safety, needles) sit in each supplier's own section.
FOB / unit · USD
Kangyou
Yesomed
Qiaosend
1 ml
$0.0145
$0.024
$0.022
3 ml
$0.0145
$0.022
$0.0225
5 ml
$0.0153
$0.023
$0.023
10 ml
$0.022
$0.031
$0.034
20 ml
$0.0356
$0.043
$0.050
50 ml
$0.088
—
$0.125
Insulin 0.5 / 1 ml
$0.0235
$0.030
$0.032
All prices FOB (factory-direct, USD). — = size not offered by that supplier. Kangyou is lowest in every standard size — the basis for its primary recommendation. Delivered cost (CIF Rotterdam) follows on the next page.
HIELUX
08
Landed Cost
From factory quote to delivered cost.
FOB is the factory quote. What you pay is the landed cost: FOB plus ocean freight, EU ETS and insurance to CIF Rotterdam. All three ship the same China–North Europe lane, so the freight add is near-identical (about $0.0042 per unit at full-container volume) — the cheapest quote stays the cheapest delivered.
3 ml standard · CIF Rotterdam · per unit · July 2026
Supplier
FOB
+ ship · ETS · ins
CIF · full 40HQ
CIF · trial (LCL)
Kangyou
$0.0145
+$0.0042
$0.0187
$0.0197
Yesomed
$0.022
+$0.0042
$0.0262
$0.0273
Qiaosend
$0.0225
+$0.0042
$0.0267
$0.0289
FOB: verified in writing · valid 30 days from issue. Freight layer: $4,873/40HQ + EU ETS $168 + insurance 0.3% at July 20, 2026 — repriced at booking. Trial (LCL) is higher per unit — small shipments pay more per CBM.
Delivered cost builds to $0.0187 — the market floor sits 2.2× higher
3ml standard syringe, Kangyou, USD per unit, CIF Rotterdam · July 20, 2026
One waterfall per presented supplier in client editions. Benchmark floor: July 2026 EU market range, low end.
Two prices, two clocks
FOB — the factory's price. Verified in writing with each supplier. Valid 30 days from this report's date; it moves in weeks and is renegotiated with the factory. The sourcing decision anchors here — it is what was verified, and what you hold a supplier to.
CIF — the delivered price. FOB plus ocean freight, EU ETS, insurance — and any duties or trade measures. Freight reprices daily, surcharges quarterly, tariffs with policy. The CIF figures in this report are computed at July 20, 2026 rates; your forwarder re-quotes at booking.
Compare factories on FOB. Budget delivery on the day you book.
What the numbers say
Kangyou is the primary recommendation for standard disposables: lowest FOB, MDR to 2030. Yesomed is the only presented option for safety and auto-disable (WHO PQS) lines. Qiaosend covers needles, backup supply, and low-MOQ entry. The three are not interchangeable — they cover different parts of a supply chain.
HIELUX
09
Savings Analysis
What this means in dollars.
What this assumes
Volume and SKU mix follow the client profile on page 03. Current spend is estimated against the July 2026 EU market benchmark (tender corridors and import pricing). New spend uses verified factory-direct pricing from the three presented suppliers. A client edition rebases every row to the buyer's actual SKU mix and current buying prices — the client's own numbers are the base, not the benchmark.
Current annual spend
$114K – $173K
Estimated · July 2026 market benchmark
New annual spend
$53,000
Verified · cost-optimized allocation
Saved annually
$61,000 – $120,000
Against report cost of $1,500 · payback within first order cycle
Verified prices land 41–59% under the market band
Market benchmark range vs verified factory-direct landed cost · US cents per unit · July 2026
3ml standard1,200,000 units · Kangyou
4.26.5
1.87¢
−55%
$28K–$56Ksaving / yr
5ml standard400,000 units · Kangyou
4.87.0
1.97¢
−59%
$11K–$20Ksaving / yr
10ml standard200,000 units · Kangyou
6.29.0
2.80¢
−55%
$7K–$12Ksaving / yr
1ml insulin300,000 units · Kangyou
5.28.0
3.05¢
−41%
$6K–$15Ksaving / yr
3ml safety200,000 units · Yesomed
6.510.0
2.75¢
−58%
$8K–$14Ksaving / yr
Hypodermic needle200,000 units · Yesomed
1.62.7
1.30¢
$1K–$3Ksaving / yr
0¢2¢4¢6¢8¢10¢
Band: July 2026 EU market benchmark. Dot: verified landed cost, CIF Rotterdam, Jul 20, 2026.
Breakdown by SKU category
SKU category
Volume
Market range
Recommended
Y1 savings
3ml standard syringe
1,200,000
$0.042 – $0.065
Kangyou · $0.0187
$28K – $56K
5ml standard syringe
400,000
$0.048 – $0.070
Kangyou · $0.0197
$11K – $20K
10ml standard syringe
200,000
$0.062 – $0.090
Kangyou · $0.0280
$7K – $12K
1ml insulin syringe
300,000
$0.052 – $0.080
Kangyou · $0.0305
$6K – $15K
Safety syringe 3ml
200,000
$0.065 – $0.100
Yesomed · $0.0275
$8K – $14K
Standard hypodermic needle
200,000
$0.016 – $0.027
Yesomed · $0.0130
$1K – $3K
Market benchmark, July 2026, USD: EU commodity-syringe tender corridor $0.054–$0.16/unit with a realized $0.087 award; safety-engineered corridor $0.22–$0.65 (hospital-facing ceilings; distributor buy-side sits below). Savings are gross of switching costs and working capital, rounded to the nearest $1,000; rows sum to the headline. Allocation strategy follows.
HIELUX
10
Allocation Strategy
Two ways to deploy these findings.
Two ways to allocate 2.5M units across the three presented suppliers. Each optimises for a different priority.
Strategy A
Cost-optimized
SKU-by-SKU matching to lowest-cost qualified supplier. Maximum landed-cost savings.
Kangyou · 84%
Yesomed · 16%
Allocation
Standard disposables + insulin · Kangyou
Safety syringes + needles · Yesomed
Backup / needle alternative · Qiaosend
Estimated annual
~$53,000
$61K – $120K saved vs market benchmark
Trade-offs
Three supplier relationships · separate QA processes and EUAR coordination per origin · best per-unit pricing on every SKU
Strategy B
Operationally-simple
Concentrated primary supplier with one backup. A cost premium of ~$12K/yr buys operational simplicity and supply priority.
Yesomed · 70%
Kangyou · 30%
Allocation
Primary (~70%) · Yesomed covers every SKU type — standard, safety, auto-disable and insulin — under one CE MDR + ISO 13485 + WHO PQS cert stack
Backup (~30%) · Kangyou cost backstop on standard disposables; MDR-confirmed
Estimated annual
~$65,000
$49K – $108K saved vs market benchmark
Trade-offs
Two supplier relationships · one primary supplier covers every SKU type under a single CE MDR / ISO 13485 cert stack · supply chain priority during constraints · ~$12K higher annual cost
Which strategy fitsStrategy A suits buyers with procurement infrastructure to run three supplier relationships and want maximum per-unit savings. Hospital procurement groups with established EU MDR processes typically operate here.
Strategy B suits buyers with leaner procurement teams who prefer to consolidate every SKU type with one qualified primary supplier, or supply chains where stockout risk carries higher commercial cost than the ~$12K per-year premium. Distributors who value a single primary relationship over per-SKU price optimisation typically operate here.
HIELUX
11
Supplier 01 of 03
Kangyou Medical
Changzhou, Jiangsu Province, China · FOB Shanghai · en.kym.cn
Best fit: Standard disposable syringes · Primary EU MDR-compliant supplier · Lowest landed cost
CE MDR · Valid March 2030
ISO 13485
EU Authorised Representative: Shanghai International Holding Corp. GmbH, Europe. Total facility 66,700m², Class 100,000 cleanroom 15,000m².
Insulin Syringes
Size
FOB/unit
MOQ
0.5ml / 1ml
$0.0235
200,000
Standard disposable and insulin pricing for all three factories sits side-by-side in the matrix on page 07. Supplier pages carry only factory-specific lines and terms.
Sales contact — Shirley
Provided upon engagement
FOB Port — Shanghai
HIELUX
12
Supplier 01 · Assessment
Kangyou Medical
Changzhou, Jiangsu · FOB Shanghai
Profile
Kangyou carries the strongest regulatory standing of the three presented — CE MDR valid to March 2030, EUAR held by Shanghai International Holding Corp. GmbH. A complete EU compliance chain. Product range includes CE MDR-certified surgical staplers (anorectal, linear, tube, skin) alongside syringes, infusion sets, and blood transfusion sets.
The economic case
Lowest FOB pricing for standard disposable syringes in this evaluation — $0.0145/unit on 3ml FOB Shanghai. At full 40HQ volume, landed cost to Rotterdam is $0.0187/unit. For a distributor whose primary requirement is standard disposables for EU hospital procurement, this is the primary recommendation. Pricing at MOQ stage is fixed. Volume terms — price adjustment, priority allocation, extended payment — open with a documented commitment of quantity and timeline.
Financial standing note
Kangyou has been rated Changzhou AAA credit-grade enterprise and holds the "Jiangsu Medical Device Manufacturing Enterprises Integrity Unit" designation. For buyers conducting supplier financial due diligence, these are verifiable public designations. For orders above USD 50,000, a full financial due diligence check is recommended independently of this report.
Sales contact — Shirley
Provided upon engagement
FOB Port — Shanghai
HIELUX
13
Supplier 02 of 03
Wuxi Yesomed
Wuxi, Jiangsu Province, China · FOB Shanghai · en.chinasyringe.com
Best fit: Safety & auto-disable syringes · WHO PQS · deepest certification stack
CE MDR
ISO 13485
FDA · K053519 · Since 2006
WHO PQS · E008 · AD syringe
+ registered in 100+ markets
Wholly-owned subsidiary of Suzhou Tianhua Super Clean Technology Co., Ltd. (Shenzhen Stock Exchange: 300390). Registered capital RMB 60 million. Factory 50,000m², clean workshop 11,000m². 24 domestic patents (11 invention, 13 utility model) + patents in USA, Europe, India, Indonesia, PCT. Products exported to approximately 100 countries.
MOQ — Syringes
200,000 units
MOQ — Needles
1,000,000 units
Lead time
30 days from deposit
Payment terms
30% deposit · 70% before shipment
FDA clearance
K053519 · Safety syringe · since 2006
WHO PQS
Auto-disable syringe only · PQS E008
Annual production capacity
Self-destructing
600 million units
Safety syringes
500 million units
Standard disposable
400 million units
Insulin syringes
200 million units
High-pressure syringes
4 million units
Surgical instruments
2 million sets
HIELUX
14
Wuxi Yesomed · Pricing
FOB Shanghai · All prices USD · EO sterilised · Latex-free · Medical-grade PP
Auto-Disable (AD) · WHO PQS E008 Certified
Size
FOB/unit
MOQ
Carton
0.05ml
$0.025
200,000
3,000
0.5ml
$0.020
200,000
3,000
Re-Use Prevention (RUP)
Size
FOB/unit
MOQ
Carton
1ml
$0.028
200,000
3,000
3ml
$0.0205
200,000
2,400
5ml
$0.0215
200,000
2,000
10ml
$0.033
200,000
1,600
Insulin Syringes · MDR · ISO 13485
Size
FOB/unit
Size
FOB/unit
0.3ml
$0.032
1ml
$0.030
0.5ml
$0.030
—
—
Needles · FDA · MDR · ISO 13485
Product
Gauge
FOB/unit
MOQ
Safety needle
18G–30G
$0.022
1,000,000
Standard needle
18G–30G
$0.007
1,000,000
Insulin pen needle
29G–32G
$0.019
200,000
Safety and standard needle MOQ is 1,000,000 units. Insulin pen needle MOQ is 200,000 units.
Standard disposable lines for all three factories are compared in the matrix on page 07; this page covers the specialty lines only Yesomed manufactures. All prices FOB Shanghai. WHO PQS covers auto-disable syringe (E008) only — does not extend to needles or standard disposable lines. High-pressure syringes (imaging use) available — request pricing separately. 2-Part Luer Slip available on request at marginally lower pricing.
Yesomed's legal entity is Wuxi Yushou Medical Appliances Co., Ltd., a wholly-owned subsidiary of Suzhou Tianhua Super Clean Technology — Shenzhen-listed (300390) since 2014, which acquired Wuxi Yushou in 2015. The parent's capital structure and filings are public. Initial contact requires persistence. Once established, documentation, samples, and responses arrive without delay.
Certification depth
Yesomed's regulatory clearances span the most markets of the three presented. FDA clearance K053519 has been current since 2006. WHO PQS E008 covers auto-disable syringes only — it does not extend to needles or standard disposables. It is the only supplier in this evaluation holding WHO PQS alongside CE MDR and ISO 13485 — the combination EU safety-syringe supply requires.
Where to use them
Safety syringes — AD, RUP, and safety clip — are this factory's core capability: annual safety-syringe capacity of 500 million units, 24 domestic patents on the line. For standard luer lock at volume, Kangyou delivers a lower landed cost. For safety lines, imaging (high-pressure) syringes, or any line requiring WHO PQS auto-disable certification, Yesomed is the first call. Volume terms open with a documented commitment — not at MOQ inquiry stage.
Sales contact
Provided upon engagement
FOB Port — Shanghai
HIELUX
16
Supplier 03 of 03
Qiaosend Medical
Zibo, Shandong Province, China · FOB Qingdao · qiaosend.com.cn
Best fit: Needle sourcing · Backup supply line · Low-MOQ entry · Export-specialist structure
CE MDR · Valid July 2029
ISO 13485
Sino-US joint venture. Subsidiary of Shandong Qiaopai Group Co., Ltd. Registered capital USD 3.5 million. EU Authorised Representative: MedNet EC-REP GmbH. EO sterilisation. Export-only operation — domestic China market handled separately by parent Qiaopai entity. Established 2006. Cleanroom 10,000m². Supplies 30+ countries across Europe, Middle East, South America, Southeast Asia, Africa.
Needles — lowest pricing in this evaluation
Product
FOB/unit
MOQ
Hypodermic needle 18G
$0.009
100,000
Hypodermic needle 19G–27G
$0.0085
100,000
Insulin syringe 0.5ml / 1ml
$0.032
200,000
Standard-line pricing for all three factories: matrix, page 07. This page lists the needle lines Qiaosend leads on.
Assessment
Qiaosend is an export-only Sino-US joint venture; domestic China sales sit with the parent Qiaopai entity. CE MDR valid to July 2029, EUAR with MedNet EC-REP GmbH. Standard syringe pricing runs above Kangyou for comparable SKUs; needle pricing is the lowest in this evaluation. Position for this profile: needle supplier, backup line for syringes, and low-MOQ entry at 100,000 units.
Sales contact — Merlin
Provided upon engagement
FOB Port — Qingdao
HIELUX
17
Evaluated · Not Recommended
Zhejiang INI Medical
Zhejiang INI Medical Technology Co., Ltd. · Wenzhou, Zhejiang
FOB Ningbo / Shanghai · inimd.com
Removed at presentation stage — MDR transition unresolved
01
MDR status
MDD expired November 2025 — full MDR certificate pending
MDR application approved May 2024; the certificate has not yet issued. Under EU 2023/607 transitional provisions a legacy MDD certificate backed by a timely MDR application is generally deemed valid to 2027–2028, subject to conditions — but deemed-valid status is conditional, and NL/BE hospital tenders increasingly require an issued MDR certificate.
02
Why price does not override
A pending certificate is a supply risk, not a discount opportunity
Second-lowest standard-syringe FOB of the six evaluated ($0.0165 on 3ml) and the lowest MOQ (100,000 units). Neither offsets certification uncertainty for a hospital-channel profile under current EU MDR enforcement.
MOQ
100,000 units
FOB Port
Ningbo / Shanghai
Certifications held
ISO 13485 (TUV Rheinland) · MDR pending
Facility
26,000m² · 400+ employees
Conditions for reconsideration
If the full MDR certificate issues, INI re-enters evaluation: its pricing and MOQ would place it as a secondary supplier for standard disposables and a primary source for specialty needle categories. Hielux monitors the certificate status and notifies the client on issuance.
HIELUX
18
Evaluated · Not Recommended
Guangdong Haiou
Guangdong Haiou Medical Apparatus Co., Ltd. · Puning City, Guangdong
FOB Shantou · haiou.net.cn
Did not meet profile criteria
01
MOQ Mismatch
500,000 unit minimum — 2.5× above profile requirement
A first-order cash commitment out of proportion to this profile's volumes and risk tolerance.
02
No Direct Relationship
Evaluation based on price sheet only — no engagement conducted
No direct communication, no named contact engagement, no sample evaluation. Hielux does not recommend suppliers where direct independent engagement has not occurred prior to the report.
03
Port Limitation
FOB Shantou — limited direct service to Rotterdam
Fewer direct vessel services to Rotterdam than Shanghai, Ningbo, or Qingdao. Transit reliability and carrier selection are materially more limited on this lane.
MOQ
500,000 units
FOB Port
Shantou
Certifications held
FDA · WHO PQS · CE · ISO 13485
Relationship status
Price sheet only · no direct contact
Conditions for reconsideration
Haiou holds FDA, WHO PQS, CE, and ISO 13485. If direct engagement is established, samples are evaluated, and order volume justifies 500,000 units, Haiou becomes viable — particularly for safety syringe lines, where its pricing is competitive at scale.
HIELUX
19
First Order Reference
Typical first order timeline — Asia to Rotterdam
Timelines are indicative only. Actual schedules vary by supplier responsiveness, sample evaluation duration, and production scheduling.
Day 1–3
Initial contact. NDA if required. Confirm product specifications and request proforma invoice.
Day 4–10
Sample dispatch from factory. Courier charges paid by buyer. One sample order standard — product typically at no cost.
Day 11–20
Sample evaluation against specification. ISO 11135 sterilisation documentation review. Clinical team sign-off if required.
Day 21–35
Final quotation. Purchase order issued. Deposit transferred (typically 30%). MOQ pricing is fixed at this stage.
Day 36–65
Production. 30 days standard lead time from deposit receipt. Balance payment (70%) due before shipment.
Day 66–110
Sea freight — Shanghai/Ningbo to Rotterdam via Cape of Good Hope. 35–45 days transit. LCL or FCL by volume.
Day 111–120
Customs clearance Rotterdam. Import duty, VAT, and EORI requirements are buyer responsibility — verify with customs broker before shipment. Delivery to warehouse.
HIELUX
20
Next Steps
What to do now — and how Hielux can help.
Your immediate actions
01
First · Kangyou
Request Kangyou samples for your primary SKUs (3ml, 5ml, 10ml luer lock). Specify your product requirements in writing — material spec, packaging, labelling — to receive the correct sample configuration.
02
Parallel · Yesomed
If safety syringes are in your product range, initiate Yesomed qualification in parallel. Request AD and RUP samples; the EU MDR and ISO 13485 documentation is already provided with this report.
03
Medium term
Designate Qiaosend as backup needle supplier. Confirm needle specifications and request a sample order. This relationship can be maintained at low effort as a qualified backup source.
04
Before first PO
The current CE certificates (with scope confirmation) are provided with this report. Before your first PO, request the proforma invoice from the supplier — and do not transfer the deposit without a signed PI in hand.
From here, Hielux can manage
Supplier qualification — sample coordination and testing against your specs. (Certificates in this report are already verified; Hielux re-checks on renewal or scope change.) Volume contract structuring — defined quantity and timeline to open pricing that doesn't exist at first-order stage. Sourcing engagement — we manage communication, negotiation and order coordination on your behalf. Ongoing supply-chain management — repeat orders, pricing reviews, backup activation and market intelligence.
Advisory
Hielux Advisory
Email
advisory@hieluxmt.com
Singapore
+65 3 1255276
HIELUX
21
Appendix
Incoterms, scope & disclaimer
Incoterms reference
FOB — Free On Board
Seller delivers goods onto the vessel at origin port. Buyer assumes all costs and risk from that point — ocean freight, insurance, destination charges, import duties. All prices in this report are FOB.
CIF — Cost, Insurance & Freight
Seller pays ocean freight and insurance to the destination port. Buyer assumes risk once goods are loaded at origin but seller arranges and pays for transit. All landed cost calculations in this report are CIF Rotterdam.
LCL — Less than Container Load
Shipment shares container space with other cargo. Charged per CBM (cubic metre). Used for MOQ-level orders. Higher per-unit freight cost than FCL. Suitable for trial orders and initial qualification shipments.
FCL — Full Container Load
Entire container dedicated to one shipment. Charged per container. Lower per-unit freight cost. 40HQ (high-cube 40-foot) is the standard container used for medical consumables — approximately 76 CBM usable volume.
EU ETS Surcharge
Carrier surcharge for EU Emissions Trading System compliance on voyages involving EU ports. Rate used: $168 per 40HQ and ~$25 per LCL shipment — current market rate confirmed by Searoutes and CMA CGM (2026, Asia–North Europe lane — full ETS phase-in). Rates are revised quarterly by carriers. Verify with freight forwarder at booking.
DDP — Delivered Duty Paid
Seller delivers goods to buyer's premises, all costs and duties paid. Not the default terms for suppliers in this report — all pricing is FOB. DDP is available from some suppliers on request and typically adds 8–15% to FOB price on this lane.
Scope of this report
CIF Rotterdam is the boundary of this report
This report covers supplier evaluation, FOB pricing, and landed cost calculation to CIF Rotterdam. Import duties, customs clearance, EORI registration, VAT, and any post-arrival logistics are the buyer's responsibility and outside the scope of this engagement. Buyers should verify applicable import duties and trade measures with their customs broker before placing orders. Note: the EU's International Procurement Instrument measure on Chinese medical devices (in force since June 2025) can cap Chinese-origin content in EU public-procurement tenders at or above €5 million — material where the supply feeds public hospital tenders.
Disclaimer
All pricing, certification status, MOQ, lead time, and freight data was sourced directly from named supplier representatives and verified against available public records at the time of preparation (July 2026). Certifications remain subject to renewal, suspension, or scope change after that date; Hielux re-verifies on renewal. FOB quotes are verified in writing and valid 30 days from issue. Freight, EU ETS, and duty components reprice continuously — daily for freight; CIF figures are calculated at July 20, 2026 and final delivered cost is set at booking. Hielux Advisory makes no warranty as to the fitness of any supplier for any specific regulatory, clinical, or commercial purpose, and assumes no liability for decisions made on the basis of this report. Factory audit and legal review are the buyer's responsibility prior to commercial engagement. Client reports are prepared for the named client only and are not for redistribution or resale; this sample is published by Hielux Advisory for evaluation, and the client profile shown is representative. Hielux Advisory holds no financial interest in any manufacturer featured in this report.
Prepared and signed by the Principal Consultant, Hielux Advisory — the trading name of Hielux Pte. Ltd. (UEN 202549390E), Singapore.
Hielux Advisory · Sample Report · Published for evaluation
July 2026 · FOB quotes valid 30 days · Freight repriced at booking · The client profile in this sample is representative. All supplier, certification, pricing, and freight data is real and was verified as described.
Download PDF
Hielux Advisory
Download the report
Enter your email and the PDF downloads right away. We may share occasional sourcing intelligence — unsubscribe anytime.